论文部分内容阅读
目的:探讨血脂康胶囊对动脉粥样硬化大鼠血脂及血清C反应蛋白的影响。方法:健康成年大鼠24只,随机分成假手术组(Sham组,n=8),动脉粥样梗化模型组(AS组,n=8),血脂康治疗组(XZK组,n=8)。4w后,测定血液流变学参数,用自动生化分析仪测定总胆固醇(TC)、三酰甘油(TG)、血清低密度脂蛋白胆固醇(LDL-C),酶联免疫吸附法(ELISA)检测血清CRP水平。结果:与Sham组相比,AS组和XZK治疗组大鼠全血的切粘度、血清的TC、TG、LDL-C、CRP水平升高(均P<0.05);与AS组比较,XZK治疗组大鼠全血的切粘度、血清的TC、TG、LDL-C、CRP水平降低(均P<0.05)。结论:血脂康胶囊能降低动脉粥样硬化大鼠血清TC、TG、LDL-C,可能机制之一是通过降低血清C反应蛋白的水平。
Objective: To investigate the effect of Xuezhikang on serum lipids and serum C-reactive protein in atherosclerotic rats. Methods: Twenty-four healthy adult rats were randomly divided into four groups: Sham operation group (n = 8), atherosclerosis model group (AS group, n = 8), and Xuezhikang treatment group ). After 4 weeks, the parameters of hemorheology were determined, and the levels of total cholesterol (TC), triglyceride (TG), serum LDL-C and ELISA were measured by automatic biochemical analyzer Serum CRP levels. Results: Compared with Sham group, the whole blood viscosity, serum TC, TG, LDL-C and CRP levels in AS and XZK treatment groups were significantly increased (all P <0.05) The whole rat blood viscosity, serum TC, TG, LDL-C, CRP levels decreased (all P <0.05). Conclusion: Xuezhikang capsule can reduce serum atherosclerosis TC, TG, LDL-C, one of the possible mechanisms by reducing the level of serum C-reactive protein.